Ritlecitinib, an oral JAK3/TEC family kinase inhibitor, reduces immune biomarkers in active lesions and increases melanocyte products in stable lesions in patients with non-segmental vitiligo (NSV)

被引：0

作者：

Guttman-Yassky, E. ^{[1
]}

Peeva, E. ^{[2
]}

Del Duca, E. ^{[1
]}

Facheris, P. ^{[1
,3
]}

Bar, J. ^{[1
,4
]}

Shore, R. N. ^{[5
]}

Cox, L. A. ^{[6
]}

Sloan, A. ^{[2
]}

Thaci, D. ^{[7
]}

Ganeson, A. ^{[8
]}

Han, G. ^{[9
]}

Ezzedine, K. ^{[10
]}

Yamaguchi, Y. ^{[11
]}

机构：

[1] Icahn Sch Med Mt Sinai, New York, NY USA

[2] Pfizer Inc, Cambridge, MA USA

[3] IRCCS Humanitas Res Hosp, Milan, Italy

[4] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel

[5] Ronald N Shore Dermatol, Rockville, MD USA

[6] Pfizer, Basking Ridge, NJ USA

[7] Univ Lubeck, Lubeck, Schleswig Holst, Germany

[8] Univ Calif Irvine, Irvine, CA USA

[9] Hofstra Northwell, Donald & Barbara Zucker Sch Med, New Hyde Pk, NY USA

[10] Henri Mondor Hosp, Dermatol, Creteil, France

[11] Pfizer Inc, Collegeville, PA USA

来源：

JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2023年 / 143卷 / 05期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

1187

引用

页码：S204 / S204

页数：1

共 7 条

[1] Ritlecitinib, a JAK3/TEC family kinase inhibitor, stabilizes active lesions and repigments stable lesions in vitiligo
Yamaguchi, Yuji
Peeva, Elena
Duca, Ester Del
Facheris, Paola
Bar, Jonathan
Shore, Ronald
Cox, Lori Ann
Sloan, Abigail
Thaci, Diamant
Ganesan, Anand
Han, George
Ezzedine, Khaled
Ye, Zhan
Guttman-Yassky, Emma
ARCHIVES OF DERMATOLOGICAL RESEARCH, 2024, 316 (07)
[2] Improvements in immune/melanocyte biomarkers with JAK3/TEC family kinase inhibitor ritlecitinib in vitiligo
Guttman-Yassky, Emma
Del Duca, Ester
Da Rosa, Joel Correa
Bar, Jonathan
Ezzedine, Khaled
Ye, Zhan
He, Wen
Hyde, Craig
Hassan-Zahraee, Mina
Yamaguchi, Yuji
Peeva, Elena
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (01) : 161 - 172.e8
[3] Ritlecitinib downregulates inflammatory biomarkers and increases melanocyte markers in the skin lesions of patients with active non-segmental vitiligo
Hassan-Zahraee, M.
Guttman-Yassky, E.
Pavel, A. B.
Del Duca, E.
Da Rosa, J. C.
Yamaguchi, Y.
Ye, Z.
He, W.
Hyde, C.
Peeva, E.
EXPERIMENTAL DERMATOLOGY, 2021, 30 : 14 - 15
[4] Ritlecitinib, an oral dual JAK3/TEC family kinase inhibitor, induces differential changes in immunological protein levels across Fitzpatrick skin types (FST) in patients with active nonsegmental vitiligo (NSV)
Peeva, E.
Yamaguchi, Y.
Ye, Z.
King, B.
Picardo, M.
Sloan, A.
Ezzedine, K.
Del Duca, E.
Estrada, Y.
Hassan-Zahraee, M.
He, W.
Hyde, C.
Bar, J.
Facheris, P.
Guttman-Yassky, E.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (05) : S208 - S208
[5] Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis
Mesinkovska, Natasha
King, Brett
Zhang, Xingqi
Guttman-Yassky, Emma
Magnolo, Nina
Sinclair, Rodney
Mizuashi, Masato
Shapiro, Jerry
Peeva, Elena
Banerjee, Anindita
Takiya, Liza
Cox, Lori Ann
Wajsbrot, Dalia
Kerkmann, Urs
Law, Ernest
Wolk, Robert
Schaefer, Gregor
JOURNAL OF DERMATOLOGY, 2024, 51 (11): : 1414 - 1424
[6] Ritlecitinib (PF-06651600), an oral JAK3/TEC inhibitor, stabilizes active lesions and promotes repigmentation of stable lesions in patients with active nonsegmental vitiligo: Results from a phase 2b, randomized, placebo-controlled, dose-ranging study
Yamaguchi, Yuji
Peeva, Elena
Shore, Ronald
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB105 - AB105
[7] Ritlecitinib (PF-06651600), an oral JAK3/TEC inhibitor, shows efficacy in patients with active nonsegmental vitiligo and either a lighter or darker Fitzpatrick skin type: Results from a phase 2b, randomized, dose-ranging study with an extension period
Peeva, Elena
Yamaguchi, Yuji
King, Brett
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB105 - AB105

← 1 →